29210287|t|Dexmedetomidine protects against oxygen-glucose deprivation/reoxygenation injury-induced apoptosis via the p38 MAPK/ERK signalling pathway.
29210287|a|Objective To investigate the protective effects of dexmedetomidine (DEX) in oxygen-glucose deprivation/reoxygenation (OGD/R) injury, which is involved in a number of ischaemic diseases. Methods An in vitro OGD/R injury model was generated using mouse Neuro 2A neuroblastoma (N2A) cells. Different concentrations of DEX were administrated to OGD/R cells. CV-65 was used to inhibit p38 microtubule associated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) signalling. Cell proliferation, cell cycle, apoptosis, and the levels of proteins related to p38 MAPK/ERK signalling and apoptosis were evaluated using Cell Counting Kit-8, flow cytometry, TdT-UTP nick end labelling and Western blot analysis, respectively. Results DEX treatment of OGD/R cells promoted cell survival and attenuated OGD/R-induced cell apoptosis. It also activated the p38 MAPK/ERK signalling pathway, increased the levels of Bcl-2, and decreased the levels of Bax and cleaved caspase-3. Treatment with the p38 MAPK/ERK inhibitor CV-65 inhibited the activation of p38 MAPK/ERK and abrogated the DEX-induced effects on cell survival and apoptosis. Conclusions DEX protects N2A cells from OGD/R-induced apoptosis via the activation of the p38 MAPK/ERK signalling pathway. DEX might be an effective agent for the treatment of ischaemic diseases.
29210287	0	15	Dexmedetomidine	Chemical	MESH:D020927
29210287	33	59	oxygen-glucose deprivation	Chemical	-
29210287	107	115	p38 MAPK	Gene	26416
29210287	116	119	ERK	Gene	26413
29210287	191	206	dexmedetomidine	Chemical	MESH:D020927
29210287	208	211	DEX	Chemical	MESH:D020927
29210287	216	242	oxygen-glucose deprivation	Chemical	-
29210287	258	261	OGD	Disease	MESH:C536050
29210287	306	324	ischaemic diseases	Disease	MESH:D004194
29210287	346	349	OGD	Disease	MESH:C536050
29210287	385	390	mouse	Species	10090
29210287	391	413	Neuro 2A neuroblastoma	CellLine	CVCL:0470
29210287	415	418	N2A	CellLine	CVCL:0470
29210287	455	458	DEX	Chemical	MESH:D020927
29210287	481	484	OGD	Disease	MESH:C536050
29210287	494	499	CV-65	Chemical	-
29210287	607	610	ERK	Gene	26413
29210287	705	713	p38 MAPK	Gene	26416
29210287	714	717	ERK	Gene	26413
29210287	801	808	TdT-UTP	Chemical	-
29210287	877	880	DEX	Chemical	MESH:D020927
29210287	894	897	OGD	Disease	MESH:C536050
29210287	944	947	OGD	Disease	MESH:C536050
29210287	996	1004	p38 MAPK	Gene	26416
29210287	1005	1008	ERK	Gene	26413
29210287	1053	1058	Bcl-2	Gene	12043
29210287	1088	1091	Bax	Gene	12028
29210287	1104	1113	caspase-3	Gene	12367
29210287	1134	1142	p38 MAPK	Gene	26416
29210287	1143	1146	ERK	Gene	26413
29210287	1157	1162	CV-65	Chemical	-
29210287	1191	1199	p38 MAPK	Gene	26416
29210287	1200	1203	ERK	Gene	26413
29210287	1222	1225	DEX	Chemical	MESH:D020927
29210287	1286	1289	DEX	Chemical	MESH:D020927
29210287	1299	1302	N2A	CellLine	CVCL:0470
29210287	1314	1317	OGD	Disease	MESH:C536050
29210287	1364	1372	p38 MAPK	Gene	26416
29210287	1373	1376	ERK	Gene	26413
29210287	1397	1400	DEX	Chemical	MESH:D020927
29210287	1450	1468	ischaemic diseases	Disease	MESH:D004194
29210287	Association	MESH:C536050	26413
29210287	Positive_Correlation	MESH:D020927	26416
29210287	Positive_Correlation	MESH:D020927	26413
29210287	Positive_Correlation	MESH:D020927	12043
29210287	Association	MESH:C536050	26416
29210287	Negative_Correlation	MESH:D020927	MESH:C536050
29210287	Negative_Correlation	MESH:D020927	12028
29210287	Negative_Correlation	MESH:D020927	12367
29210287	Negative_Correlation	MESH:D020927	MESH:D004194

